Biosimilars


Billions in health care savings America needs

Americans desperately need health care savings.

As the next generation of generic medicines, biosimilars are a commonsense solution and cost on average 30% less than originator biologics. Biologics are the single biggest driver of prescription drug spending. They account for just two percent of prescriptions filled, but close to 40 percent of all drug spending. We can’t afford to leave savings from biosimilars on the table. But with only 17 of the 28 U.S. FDA approved biosimilars on market, the lack of access and use of these life-saving therapies is costing, rather than saving, the U.S. billions of dollars.

Biosimilars Savings

Employers, providers, and patients need financial relief now more than ever. Biosimilars provide health care savings to the top 10 most expensive drugs in Medicare Part B — savings we need to help lower costs for patients, employers and Medicare.


See how biosimilars can bring Americans financial relief.

$250 Billion

How much biosimilars could save the U.S. health care system over the next decade

$1.4 Billion 

How much self-insured companies could have saved annually if insurance plans replaced just two biologics with the lower-cost biosimilars available

$1.2 Billion

How much biosimilars could save state Medicaid programs annually

Slow Biosimilar Adoption is Costing the U.S. Billions

How much savings have patients & taxpayers lost since 2018 without biosimilars?

Patients and Taxpayers Have Lost Billions
Not Using Biosimilars

Year-to-Date Lost Savings*
2018 – 2020

$22,737,270,197

Out-of-Pocket Lost Savings*
2020

$230,393,616

Year-to-Date Lost Savings*
2020

$8,431,278,736

Our Solutions

How can we act now to deliver these savings?

Congress and the Administration can make small but meaningful policy changes right now to save patients, employers and health care providers money by helping patients access these lower-cost medicines and fixing the backwards incentives stopping physicians from prescribing lower-cost biosimilars.

Latest News

The Proposed Biosimilar Shared Savings Model: A Closer Look

In recent weeks, there has been increasingly more buzz around establishing a biosimilars shared savings model for Medicare Part B drugs in the U.S. This concept has arguably been in the works — or at least on many minds — since I began writing about biosimilars in...

read more

Choice Is Vital to Biosimilar Savings Picture

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars. Several trastuzumab biosimilars have been launched this year, and 6 FDA-approved adalimumab biosimilars are lined up for...

read more

What are Biosimilars?

The promise of biosimilars means expanding treatment options for patients, potentially improving patient outcomes by increasing or providing earlier access to therapies.

Biosimilars are lower-cost alternatives to reference biologic therapies, and have no clinically meaningful differences in the safety profile, potency, and purity as compared to the reference biologics. The FDA approves biosimilars only after they meet the agency’s rigorous standards for approval. Biosimilars create new choices and provide competition in the biologics marketplace, lowering costs for patients and the health care system by providing more options when battling challenging diseases like cancers, Crohn’s and rheumatoid arthritis.